Novartis Company

Novartis is working together with Incyte Corp in the development of a Janus kinase (JAK1/JAK2) inhibitor first approved by the FDA in 2011, with indications in polycythemia vera, myelofibrosis, and acute graft-versus-host disease. Marketed as Jakafi in the U.S. by Incyte, and as Jakavi outside the U.S. by Novartis.

Incyte and Novartis said April 2 they planned to launch a Phase III clinical trial (RUXCOVID) to assess the efficacy and safety of Jakafi/Jakavi plus standard-of-care (SoC), compared to SoC therapy alone, in patients with COVID-19 associated cytokine storm.
Technology: COVID
Industry: Treatments
Headquarters: Switzerland
Founded Date: N/A
Employees Number: N/A
Funding Status: N/A

Visit Website
Register and Claim Ownership